GlassScriptPhysician profile
Carole-Lynne Singleton
NPI 1134210693
$1,103.87
in general payments reported to CMS, 2019-2025
17 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $169 · 2022: $48.80 · 2023: $222 · 2024: $328 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $276.01 | 2021-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $154.61 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $123.15 | 2024 | Arexvy |
| Janssen Pharmaceuticals, INC | $82.64 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $68.89 | 2024-2025 | Nuzyra, Xhance |
| Welch Allyn | $52.60 | 2021 | |
| Abbvie INC. | $51.62 | 2025 | |
| Amgen INC. | $48.76 | 2023-2024 | Repatha, Otezla |
| Lundbeck LLC | $46.99 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $44.74 | 2023-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.43 | 2024-2025 | Jardiance |
| Abbott Laboratories | $34.08 | 2021-2024 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $22.05 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Philips North America LLC | $19.03 | 2025 | Lm Undivided |
| Nabriva Therapeutics, Plc | $16.12 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $15.46 | 2025 | Voquezna |
| Genentech USA, INC. | $9.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carole-Lynne Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.